Home›Trial›NCT05743881
🔬NCT05743881Phase 1ACTIVE NOT RECRUITING

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Study Summary

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.

Conditions
Respiratory Syncytial VirusHuman Metapneumovirus
Interventions / Drugs
mRNA-1345mRNA-1365PlaceboNimenrix
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C53/100
Study Details
Enrollment186 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209299+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.